Atherosclerosis: A chronic inflammatory disease mediated by mast cells

Central European Journal of Immunology

Volumn 40, Issue 3, 2015, Pages 380-386

  Conti, Pio ^a   Shaik Dasthagirisaeb, Yazdami ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Athersclerosis; Inflammation; Leukocytes; Mast cells

Indexed keywords

CD4 ANTIGEN; CHEMOKINE; CYTOKINE; LIPOPROTEIN;

APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATION; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; INNATE IMMUNITY; MACROPHAGE; MAST CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 84944590204     PISSN: 14263912     EISSN: 16444124     Source Type: Journal    
DOI: 10.5114/ceji.2015.54603     Document Type: Review

References (89)

1. Rock FL, Hardiman G, Timans JC, et al. (1998): A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 95: 588-593.
2. Rosenfeld ME (2013): Inflammation and atherosclerosis: direct versus indirect mechanisms. Curr Opin Pharmacol 13: 154-160.
3. Parks BW, Lusis AJ (2013): Macrophage accumulation in atherosclerosis. N Engl J Med 369: 2352-2353.
4. Spirig R, Tsui J, Shaw S (2012): The emerging role of tlr and innate immunity in cardiovascular disease. Cardiol Res Pract 18: 1394.
5. O'Neal RM, Still WJ (1962): Pathogenesis of atherosclerosis. Fed Proc 21: 12-14.
6. Gerrity RG, Naito HK (1980): Ultrastructural identification of monocyte-derived foam cells in fatty streak lesions. Artery 8: 208-214.
7. Zhong Y, Wang X, Ji Q, et al. (2012): CD4+LAP + and CD4 +CD25 +Foxp3 + regulatory T cells induced by nasal oxidized low-density lipoprotein suppress effector T cells response and attenuate atherosclerosis in ApoE-/-mice. J Clin Immunol 32: 1104-1117.
8. Di Pietro M, De Santis F, Schiavoni G, et al. (2013): Resver-atrol in Chlamydia pneumoniae-induced foam cell formation and interleukin-17A synthesis. J Biol Regul Homeost Agents 27: 509-518.
9. Medzhitov R (2007): Recognition of microorganisms and activation of the immune response. Nature 18: 819-826.
10. Meier P, Meier R, Blanc E (2008): Influence of CD4+/CD25+ regulatory T cells on atherogenesis in patients with end-stage kidney disease. Expert Rev Cardiovasc Ther 6: 987-997.
11. Garlanda C, Dinarello CA, Mantovani A (2013): The inter-leukin-1 family: back to the future. Immunity 39: 1003-1018.
12. b∗ immature myeloid cells (IMC) promote resistance of pro-inflammatory T cells to suppression by regulatory T cells in atherosclerotic Apo E-deficient mice. PLoS One 9: e108620
13. Liu DQ, Li LM, Guo YL, et al. (2008): Signal regulatory protein alpha negatively regulates beta2 integrin-mediated mono-cyte adhesion, transendothelial migration and phagocytosis. PLoS One. 29: e3291.
14. Mallat Z, Tedgui A. (2004): Immunomodulation to combat atherosclerosis: the potential role of immune regulatory cells. Expert Opin Biol Ther 9: 1387-1393.
15. Norata GD, Marchesi P, Passamonti S, et al. (2007): Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis 191: 265-271.
16. Galkina E, Ley K. (2009): Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 27: 165-197.
17. Li M, Lin J, Wang Z, He S, Ma X, Li D (2010): Oxidized low-density lipoprotein-induced proinflammatory cytokine response in macrophages are suppressed by CD4CD25(+) Foxp3(+) regulatory T cells through downregulating toll like receptor 2-mediated activation of NF-kappaB. Cell Physiol Biochem 25: 649-656.
18. Meng X, Zhang K, Li J, et al. (2012): Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol Med 18:598-605.
19. Goldstein JD, Pérol L, Zaragoza B (2013): Role of cytokines in thymus-versus peripherally derived-regulatory T cell differentiation and function. Front Immunol 19: 155.
20. Iantorno M, Campia U, Di Daniele N, et al. (2014): Gut hormones and endothelial dysfunction in patients with obesity and diabetes. Int J Immunopathol Pharmacol 27433-27436.
21. Pucino V, De Rosa V, Procaccini C, et al. (2014): Regulatory T cells, leptin and angiogenesis. Chem Immunol Allergy 99: 155-169.
22. Bobryshev YV, Lord RS (1995): Ultrastructural recognition of cells with dendritic cell morphology in human aortic in-tima. Contacting interactions of Vascular Dendritic Cells in athero-resistant and athero-prone areas of the normal aorta. Arch Histol Cytol 58: 307-322.
23. Stoneman V, Braganza D, vvg N, et al. (2007): Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res 100: 884-893.
24. Issekutz AC, Movat HZ (1982): The effect of vasodilator prostaglandins on polymorphonuclear leukocyte infiltration and vascular injury. Am J Pathol 107:300-9.
25. Pedersen SF, Thrysøe SA, Paaske WP, et al. (2011): Determination of edema in porcine coronary arteries by T2 weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson 13: 52.
26. Hancock WW, Adams DH, Wyner LR, et al. (1994): CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury. Am J Pathol 145: 1008-1014.
27. Inagami T (1994): Atrial natriuretic factor as a volume regulator. J Clin Pharmacol 34: 424-426.
28. Wang M, Zukas AM, Hui Y, et al. (2006): Eletion of micro-somal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. See comment in PubMed Commons belowProc Natl Acad Sci USA 103: 14507-14512.
29. Schouten M, Wiersinga WJ, Levi M, et al (2008): Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83:536-45.
30. Shin HK, Kim YK, Lee JH, Hong KW (2004): Remnant li-poprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109: 1022-1028.
31. Muller C, Salvayre R, Nègre-Salvayre A, et al (2011): HDLs inhibit endoplasmic reticulum stress and autophagic response induced by oxidized LDLs. Cell Death Differ 18: 817-828.
32. Mineo C, Shaul PW (2012): Novel biological functions of high-density lipoprotein cholesterol. Circ Res 111: 1079-1090.
33. da Rocha RF, De Bastiani MA, Klamt F (2014): Bioinformat-ics approach to evaluate differential gene expression of M1/M2 macrophage phenotypes and antioxidant genes in atherosclerosis. Cell Biochem Biophys 70: 831-839.
34. El Hadri K, Mahmood DF, Couchie D, et al (2012): Thiore-doxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol 32:1445-1452.
35. Madge LA, Pober JS A (2000): A phosphatidylinositol 3-ki-nase/Akt pathway, activated by tumor necrosis factor or inter-leukin-1, inhibits apoptosis but does not activate NFkappaB in human endothelial cells. J Biol Chem 275: 15458-15465.
36. Hughes AD, Clunn GF, Refson J, et al. (1996): Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle. Gen Pharmacol 27: 1079-1089.
37. Alexandru N, Popov D, Dragan E, et al. (2013): Circulating endothelial progenitor cell and platelet microparticle impact on platelet activation in hypertension associated with hyper-cholesterolemia. PLoS One 8: e52058.
38. Foks AC, Frodermann V, ter Borg M, et al. (2011): Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. Atherosclerosis 21853-21860.
39. Yassin LM, Rojas M, Ramírez LA, et al. (2010): Monocyte activation by apoptotic cells removal in systemic lupus ery-thematosus patients. Cell Immunol 266: 52-60.
40. -mice. Cell Death Dis 19: e806.
41. Ren J, Grundy SM, Liu J, et al. (2010): Long-term coronary heart disease risk associated with very-low-density lipopro-tein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS). Atherosclerosis 211: 327-332.
42. Hoff HF, O'Neil J (1988): Extracts of human atherosclerotic lesions can modify low density lipoproteins leading to enhanced uptake by macrophages. Atherosclerosis 70: 29-41.
43. Falcone C, Bozzini S, Matrone B, et al. (2013): RAGE gene polymorphism in heart failure patients with and without an-giographic evidence of significant coronary atherosclerosis. Int J Immunopathol Pharmacol 26: 199-206.
44. Fukuda S, Horiuchi S, Tomita K, et al (1986): Acetylated low-density lipoprotein is endocytosed through coated pits by rat peritoneal macrophages. Virchows Arch B Cell Pathol Incl Mol Pathol 52: 1-13.
45. Kritas SK, Caraffa A, Antinolfi P, et al. (2014):IgE Generation and mast cell activation. Eur J Inflamm 12: 21-25.
46. Kritas SK, Saggini A, Cerulli G, et al. (2014): Relationship between serotonin and mast cells: inhibitory effect of anti-serotonin. J Biol Regul Homeost Agents 28: 377-380.
47. Kritas SK, Saggini A, Cerulli G, et al. (2014): Neuropeptide NGF mediates neuro-immune response and inflammation through mast cell activation. J Biol Regul Homeost Agents 28: 177-181.
48. Bot I, Shi GP, Kovanen PT (2015): Mast cells as effectors in atherosclerosis. Arterioscler Thromb Vasc Biol 35: 265-271.
49. Kritas SK, Saggini A, Varvara G, et al (2013): Impact of mast cells on the skin. Int J Immunopathol Pharmacol 26: 855-859.
50. Kritas SK, Saggini A, Varvara G, et al. (2013): Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents 27: 655-660.
51. Artenjak A, Ko-elj M, Lakota K, et al. (2013): High avidity anti-β2-glycoprotein I antibodies activate human coronary artery endothelial cells and trigger peripheral blood mononu-clear cell migration. Eur J Inflamm 11: 385-396.
52. Shaik-Dasthagirisaheb YB, Varvara G, Murmura G, et al (2013): Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int J Immunopathol Pharmacol 26: 327-335.
53. Conti P, Varvara G, Murmura G, et al. (2013): Comparison of beneficial actions of non-steroidal anti-inflammatory drugs to flavonoids. J Biol Regul Homeost Agents 27: 1-7.
54. Bot I, de Jager SC, Bot M, et al. (2010): The neuropeptide substance P mediates adventitial mast cell activation and induces intraplaque hemorrhage in advanced atherosclerosis. Circ Res 106: 89-92.
55. den Dekker WK, Tempel D, Bot I, et al. (2012): Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway. Arterioscler Thromb Vasc Biol 32: 1960-1969.
56. Willems S, Vink A, Bot I, et al (2013): Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. Eur Heart J 34: 3699-3706.
57. Frydas S, Varvara G, Murmura G, et al (2013): Impact of capsaicin on mast cell inflammation. Int J Immunopathol Pharmacol 26: 597-600.
58. Speranza L, Pantalone A, Saggini R, et al. (2013): Inhibitor effect of antioxidant flavonoids quercitin, and capsaicin in mast cell inflammation Eur J Inflamm 11: 353-357.
59. Galkina E, Ley K (2007): Leukocyte influx in atherosclerosis. Curr Drug Targets 8: 1239-1248.
60. Kritas SK, Saggini A, Cerulli G, et al (2014): Interrelationship between IL-3 and mast cells. J Biol Regul Homeost Agents 28: 17-21.
61. Lee M, Calabresi L, Chiesa G, (2002): Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 22: 1475-1481.
62. Raicevic G, Rouas R, Najar M, et al. (2010): Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum Immunol 71: 235-244.
63. Taub DD, Proost P, Murphy WJ, et al (1995): Monocyte che-motactic protein-1 (MCP-1),-2, and-3 are chemotactic for human T lymphocytes. J Clin Invest 95: 1370-1376.
64. Renne M, Conforti F, Camastra C, et al. (2014): Macrophage activation and patterns of inflammation in obese and non-obese women with breast carcinoma. Eur J Inflamm 12: 197-200.
65. Haley KJ, Lilly CM, Yang JH, et al. (2000): Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102: 2185-2189.
66. Conti P, Pang X, Boucher W, et al. (1997): Impact of Rantes and MCP-1 chemokines on in vivo basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 89: 4120-4127.
67. Cipollone F, Marini M, Fazia M, et al. (2001): Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21: 327-334.
68. Oliveira SH, Costa CH, Ferreira SH, et al. (2002): Sephadex induces eosinophil migration to the rat and mouse peritoneal cavity: involvement of mast cells, LTB4, TNF-alpha, IL-8 and PAF. Inflamm Res 51: 144-153.
69. McNeill E, Iqbal AJ, Patel J, et al. (2014): Contrasting in vitro vs. in vivo effects of a cell membrane-specific CC-chemo-kine binding protein on macrophage chemotaxis. J Mol Med (Berl) 92: 1169-1178.
70. Sun J, Sukhova GK, Wolters PJ, et al. (2007): Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 13: 719-724.
71. Baumruker T, Csonga R, Pursch E, et al. (2003): Activation of mast cells by incorporation of cholesterol into rafts. Int Immunol 15: 1207-1218.
72. Michel JB (2003): Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler Thromb Vasc Biol 23: 2146-2154.
73. Grewal IS, Flavell RA (1998): CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16: 111-135.
74. Willems S, van der Velden D, Quax PH, et al (2014): Circulating immunoglobulins are not associated with intraplaque mast cell number and other vulnerable plaque characteristics in patients with carotid artery stenosis. PLoS One 9: e88984.
75. Montero MT, Hernández O, Suárez Y, et al (2000): Hy-droxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153: 303-313.
76. Matusik P, Guzik B, Weber C, Guzik TJ (2012): Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice? Thromb Haemost 108: 443-456.
77. Zanin V, Marcuzzi A, Kleiner G, et al (2013): Lovastatin dose-dependently potentiates the pro-inflammatory activity of lipopolysaccharide both in vitro and in vivo. J Cardiovasc Transl Res 6: 981-988.
78. Barsotti A, Di Napoli P, Taccardi AA, et al. (2001): MK-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an e-NOS mRNA overexpression after global ischemia. Atherosclerosis 155: 53-59.
79. Vaughan CJ, Gotto AM Jr, Basson CT (2000): The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35: 1-10.
80. Rajanikant GK, Zemke D, Kassab M, et al. (2007): The therapeutic potential of statins in neurological disorders. Curr Med Chem 14: 103-112.
81. Weng Z, Zhang B, Asadi S, et al. (2012): Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One 7: e33805.
82. Malek HA, Shata A (2014): Effect of a high dose of vitamin D on a rabbit model of atherosclerosis. Int J Immunopathol Pharmacol 27: 195-201.
83. De Liso F, Bonara P, Vigna L, et al (2013): Oxidative stress and low-grade inflammatory status as cardiometabolic risk factors in Italian occupational overweight/obese subjects. Eur J Inflamm 11: 789-796.
84. Rickard A, Portell C, Kell PJ, et al. (2005): Protease-activat-ed receptor stimulation activates a Ca2+-independent phos-pholipase A2 in bladder microvascular endothelial cells. Am J Physiol Renal Physiol 288: F714-F721.
85. Porreca E, Di Febbo C, Di Sciullo A, et al. (1996): Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb Haemost 76: 99-104.
86. Zardi EM, Sambataro G, Basta F, et al. (2014): Subclini-cal carotid atherosclerosis in elderly patients with primary Sjögren syndrome: a duplex Doppler sonographic study. Int J Immunopathol Pharmacol 27: 645-651.
87. Shaik-Dasthagirisaheb YB, Varvara G, Murmura G, et al. (2013): Inhibitor effect of antioxidant flavonoids quercitin, and capsaicin in mast cell inflammation. Eur J Inflamm 11: 353-357.
88. Yoshino Y, Kohara K, Abe M, et al (2014): Missense variants of the alanine: glyoxylate aminotransferase 2 gene correlated with carotid atherosclerosis in the Japanese population. J Biol Regul Homeost Agents 28: 605-614.
89. Keum JS, Jaffa MA, Luttrell LM, et al (2014): Novel mechanism of plasma prekallikrein (PK) activation by vascular smooth muscle cells: evidence of the presence of PK activator. J Biol Regul Homeost Agents 28: 587-603.